Search Results
Your search for ,foR matches 32605 pages
Showing 4151 - 4200Researchers Uncover How Advanced Melanoma May Resist Treatment at the End of Life
Researchers have revealed the potential mechanisms contributing to treatment resistance in patients with melanoma at the end of life, according to a new study published by Spain et al in Cancer Discovery. “These results present the most detailed picture yet of what melanoma looks like at the final...
Clinical Trial Participation May Be Associated With Improved Overall Survival in Patients With Ovarian Cancer
Investigators have found that patients with platinum-resistant epithelial ovarian cancer who participate in clinical trials may have higher rates of overall survival compared with those who don’t participate in clinical trials, according to findings presented by Morton et al at the Society of...
How Do Novel Genetic Subtypes of Urothelial Carcinoma Respond to Immune Checkpoint Blockade?
In a study reported in the Journal of Clinical Oncology, Sarfaty et al identified novel genetic subtypes of urothelial carcinoma exhibiting different responses to immune checkpoint blockade. Study Details In the multicenter study, whole-exome sequencing was performed on tumor specimens from 88...
Time-Related and Financial Burdens May Impact Quality of Life for Patients With Gynecologic Cancer
Time-related and financial burdens may be detrimental to the quality of life of patients with gynecologic cancer as well as cancer survivors, according to the findings from two new studies presented by Ackroyd et al and Adjei et al at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on ...
Addition of Immunotherapy to Chemotherapy Regimen May Increase Progression-Free Survival in Patients With Advanced or Recurrent Endometrial Cancer
Adding immunotherapy to standard chemotherapy may result in significantly longer progression-free survival for patients with advanced or recurrent endometrial cancer, according to the findings from two novel studies presented by Eskander et al and Mirza et al at the Society of Gynecologic Oncology...
Addition of Gemcitabine to Cisplatin and Intensity-Modulated Radiation Therapy May Improve Outcomes for Patients With Locally Advanced Vulvar Cancer
Researchers have found that concurrent treatment with gemcitabine as well as cisplatin and intensity-modulated radiation therapy may effectively increase the pathologic complete response rates in patients with locally advanced squamous cell carcinoma of the vulva, according to findings presented by ...
Subcutaneous vs IV Administration of Medications and Fluids in Patients With Cancer: U.S. vs Canadian Cancer Center Methods
In a study reported in a research letter in JAMA Oncology, Tang et al found that the use of the subcutaneous route for administering medications and fluids in patients with cancer was highly predominant in a Canadian center, whereas use of the intravenous (IV) route was nearly universal in a U.S....
FDA Grants Full Approval to Pembrolizumab for Certain Adult and Pediatric Patients With Advanced MSI-H or dMMR Solid Tumors
On March 29, the U.S. Food and Drug Administration (FDA) granted full approval to the anti–PD-1 therapy pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tumors, as...
Researchers Find No Significant Differences in Overall Survival Among Patients With Platinum-Sensitive Recurrent Ovarian Cancer Who Received Niraparib Maintenance Therapy vs Placebo
Researchers have found no significant differences in overall survival between patients with platinum-sensitive recurrent ovarian cancer who received maintenance therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib or placebo, according to new findings presented by Matulonis et...
Positive Outcomes Demonstrated in Patients With Ovarian Cancer Treated With Olaparib Prior to Surgical Intervention and Subsequent Chemotherapy
Treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib prior to surgical intervention and chemotherapy has demonstrated the potential for favorable surgical options, manageable adverse events, and positive health outcomes in patients with ovarian cancer who have a germline...
Atezolizumab May Be an Effective Primer for Chemoradiation in Patients With Locally Advanced Cervical Cancer
After comparing the efficacy of the anti–PD-L1 inhibitor atezolizumab prior to and concurrently with chemoradiation, researchers have indicated favorable outcomes for 2-year disease-free survival and demonstrated evidence of improved immunogenicity with neoadjuvant atezolizumab in patients with...
RUBY Trial: Dostarlimab Plus Carboplatin and Paclitaxel in Advanced Endometrial Cancer
Adding immunotherapy to standard chemotherapy for the first-line treatment of advanced or the first recurrence of endometrial cancer significantly improved progression-free survival compared to chemotherapy alone, according to data presented by Mansoor Raza Mirza, MD, and colleagues at the March...
Antibiotic Use and Survival Among Patients With Metastatic Pancreatic Cancer Receiving Specific Chemotherapy Regimens
In a retrospective cohort study reported in JAMA Network Open, Fulop et al found that perichemotherapy use of antibiotics was associated with improved survival in patients with metastatic pancreatic ductal adenocarcinoma receiving first-line gemcitabine-based chemotherapy, but not in those...
Lower-Dose Regimens of Exemestane in Postmenopausal Patients With Stage 0 to II ER-Positive Breast Cancer
In a phase IIb trial reported in JAMA Oncology, Serrano et al found that exemestane at 25 mg three times weekly was noninferior to the standard dosing of 25 mg once daily in terms of serum estradiol reduction among postmenopausal patients with stage 0 to II estrogen receptor (ER)-positive breast...
Brown Adipose Tissue May Not Be Associated With Cancer Cachexia, May Not Worsen Cancer Mortality
Brown adipose tissue may not be associated with cachexia, according to an article published by Eljalby et al in the American Journal of Physiology Endocrinology and Metabolism. The findings also suggested that brown adipose tissue does not increase cancer mortality. Background Brown adipose tissue...
Risk of Cervical Cancer May Be Twice as High in Patients With Mental Illnesses
Patients who have a mental illness, neuropsychiatric disability, or substance use disorder may be less likely to undergo gynecological smear tests and may have over twice the risk of developing cervical cancer, according to a new study published by Hu et al in The Lancet Public Health. The findings ...
New Prognostic Staging System for De Novo Metastatic Breast Cancer
In a study reported in the Journal of Clinical Oncology, Jennifer K. Plichta, MD, MS, and colleagues formulated a novel prognostic staging system for de novo metastatic breast cancer. Study Details The staging system was developed using data from 42,467 patients from the National Cancer Database...
Change in Frailty Status Among Older Patients Undergoing Locoregional Therapy for Early-Stage Breast Cancer
In a cohort study reported in a research letter in JAMA Surgery, Minami et al found that frailty status worsened in a sizable proportion of older patients receiving locoregional therapy—including lumpectomy or mastectomy—for early-stage breast cancer. Baseline robust status and mastectomy were...
Naporafenib Plus Trametinib in Advanced NRAS-Mutant Melanoma
As reported in the Journal of Clinical Oncology by de Braud et al, findings in the expansion cohort of a phase Ib trial indicate activity with the combination of the BRAF/CRAF kinase inhibitor naporafenib and trametinib in patients with advanced or metastatic NRAS-mutant melanoma. Study Details In ...
Significance of the MGUS-Like Phenotype in Patients With Multiple Myeloma and Light Chain Amyloidosis
In a study reported in the Journal of Clinical Oncology, Burgos et al developed an algorithm to identify patients with multiple myeloma and light-chain amyloidosis who have the monoclonal gammopathy of undetermined significance (MGUS)-like phenotype, as well as identified the association of the...
Poorer Survival in Stage III Colon Cancer With Greater Inflammation After Surgery and Prior to Adjuvant Therapy
In a study reported in JAMA Oncology, En Cheng, MD, PhD, of Kaiser Permanente Northern California, Jeffrey Meyerhardt, MD, MPH, FASCO, of Dana-Farber Cancer Institute, and colleagues found that higher levels of inflammatory biomarkers measured after surgery but before starting chemotherapy were ...
Smoking Cessation Intervention in Patients With a History of Cervical Intraepithelial Neoplasia or Cervical Cancer
In a study reported in the Journal of Clinical Oncology, Vidrine et al found that a smoking cessation intervention was not effective among patients with a history of cervical intraepithelial neoplasia or cervical cancer. Study Details In the trial, 194 evaluable patients who reported current...
Obesity May Contribute to Breast Cancer Risk in High-Risk Patients With BRCA Mutations
Obesity may spur DNA damage in the breast tissue of patients who carry BRCA1 or BRCA2 mutations, possibly contributing to breast cancer development in patients who are already at a higher risk of the disease, according to a new study published by Bhardwaj et al in Science Translational Medicine....
Lower-Income Patients With Early-Stage Esophageal Adenocarcinoma May Face Disparities in Cancer Care and Higher Mortality Rates
Patients with early-stage esophageal adenocarcinoma from lower-income households may be significantly less likely to receive a potentially life-saving treatment and may be more likely to die from the disease, according to a new study published by Geng et al in Clinical Gastroenterology and...
First-Line Systemic Treatments in Metastatic Castration-Sensitive Prostate Cancer
In a systematic review and meta-analysis reported in JAMA Oncology, Riaz et al found that first-line triplet therapy in metastatic castration-sensitive prostate cancer did not appear to offer an overall survival advantage vs androgen pathway inhibitor doublet therapy. As stated by the...
FDA Issues Draft Guidance Aimed at Improving Oncology Clinical Trials for Accelerated Approval
On March 24, the U.S. Food and Drug Administration (FDA) issued draft guidance, Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics, regarding clinical trial design considerations to support accelerated approval applications. The accelerated approval pathway is...
It Is Time to Close the Gap in Cancer Care
Cancer is a leading cause of death in every country worldwide.1 In 2020, almost 10 million people died of cancer, a number that is expected to rise to 16.3 million by 2040.2 In addition, cancer incidence continues to grow, driven by an aging and growing population and changes in the prevalence and...
ASCO Celebrates the Cancer Moonshot on Its Relaunch Anniversary
“Dedicated to making a world of difference in cancer care, the American Society of Clinical Oncology and its affiliated organization, the American Association of Clinical Oncology (ASCO), laud the goals, progress, and continued potential of the Cancer Moonshot initiative. Having the full support of ...
Eight Oncology Health Systems Participating in Efforts to Improve Vaccination Rates Among High-Risk Adults
ASCO is working with eight oncology health systems to develop, test, and measure strategies to improve immunization rates as part of an initiative with the Council of Medical Specialty Societies (CMSS) to improve vaccination rates among high-risk adults. Through this project, known as Specialty...
2024 ACA Proposal Aims to Reduce Health-Care Coverage Gaps
ASCO submitted comments in response to the Centers for Medicare & Medicaid Services’ (CMS) Patient Protection and Affordable Care Act 2024 Notice of Benefit and Payment Parameters proposed rule. ASCO’s comments support proposals aimed at reducing or eliminating gaps in health-care coverage, and ...
Three Models Testing Ways to Lower Drug Costs Outlined in Health and Human Services Report
On February 14, 2023, the Centers for Medicare & Medicaid Services (CMS) announced that the Secretary of the Department of Health and Human Services (HHS) selected three models aiming to address high prescription drug costs for testing by the Center for Medicare and Medicaid Innovation (CMMI)....
ASCO Updates Guideline on Sacituzumab Govitecan-hziy in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
ASCO has released a rapid recommendation update to the guideline on chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor–negative metastatic breast cancer, addressing the use of sacituzumab govitecan-hziy in patients with endocrine-resistant, hormone receptor–positive,...
DESTINY-Breast03: T-DXd Improves Overall Survival vs T-DM1 in Previously Treated HER2-Positive Metastatic Breast Cancer
As reported in The Lancet by Sara A. Hurvitz, MD, of the David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, and colleagues, updated results of the phase III DESTINY-Breast03 trial showed significantly improved overall survival with...
Sotorasib Improves Progression-Free Survival vs Docetaxel in Previously Treated Advanced NSCLC With KRAS G12C Mutation
As reported in The Lancet by Adrianus Johannes de Langen, MD, PhD, of the Netherlands Cancer Institute, Amsterdam, and colleagues, the phase III CodeBreaK200 trial has shown a small but significant improvement in progression-free survival with sotorasib vs docetaxel in previously treated advanced...
Idecabtagene Vicleucel vs Standard Regimens in Patients With Relapsed or Refractory Multiple Myeloma
As reported in The New England Journal of Medicine by Paula Rodriguez-Otero, MD, PhD, of Clínica Universidad de Navarra, Pamplona, Spain, and colleagues, an interim analysis of the phase III KarMMa-3 trial has shown superior progression-free survival with the B-cell maturation antigen–directed...
Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
On January 27, 2023, pirtobrutinib was granted accelerated approval for treatment of relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.1 Pirtobrutinib is a noncovalent inhibitor of BTK. Supporting Efficacy...
10 Facts About Colorectal Cancer From the Colorectal Cancer Alliance
March is widely recognized worldwide as Colorectal Cancer Awareness month. Several advocacy groups and professional organizations recognize Colorectal Cancer Awareness month by promoting screening for eligible individuals and working to increase awareness. Here, the Colorectal Cancer Alliance, an...
Studies of Novel Therapeutic Approaches Highlighted During Colorectal Cancer Awareness Month at Dana-Farber
Colorectal cancer is the third most common cancer among men and women of all ages in the United States and is on track to be the leading cause of cancer death in adults younger than 50 by 2030. The alarming rise of colorectal cancer in people younger than age 50 prompted the U.S. Preventive...
Regular Approval for Dostarlimab-gxly in dMMR Recurrent or Advanced Endometrial Cancer
On February 9, 2023, dostarlimab-gxly was granted regular approval for adults with mismatch repair–deficient (dMMR) recurrent or advanced endometrial cancer, as determined by a U.S. Food and Drug Administration–approved test, whose disease has progressed on or following a prior platinum-containing...
Association of Baseline and Subsequent Cardiovascular Health Metrics to Risk for Incident Cancers
In an analysis from the French GAZEL study reported in JACC: CardioOncology, Thomas Van Sloten, MD, PhD, of the Université Paris Cité, Institut National de la Santé et de la Recherche Médicale, Paris, and colleagues found that better cardiovascular health (CVH) scores at baseline and improvement in ...
Racial/Ethnic Disparities in All-Cause and Cardiovascular Mortality Among U.S. Patients With Cancer
In an analysis reported in JACC: CardioOncology, Cenjing Zhu, MPhil, of the Department of Chronic Disease Epidemiology, Yale University, and colleagues found that Black patients with cancer in the United States were at increased risk of all-cause mortality and cardiovascular (CVD) mortality...
Rucaparib vs Physician’s Choice of Single-Agent Therapy in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
As reported in The New England Journal of Medicine by Karim Fizazi, MD, PhD, of Gustave Roussy Institute, Paris-Saclay University, and colleagues, the phase III TRITON3 trial has shown significantly improved progression-free survival with rucaparib vs physician-selected single-agent therapy in the...
Expert Point of View: Xin Gao, MD
Xin Gao, MD, Assistant Professor, Harvard Medical School, Genitourinary Cancers Program, Mass General Cancer Center, commented on the results from TROPHY-U-01 cohort 2. “These data add to the overall data on the efficacy of sacituzumab govitecan in patients with metastatic urothelial cancer. This...
Sacituzumab Govitecan-hziy Achieves Response After Disease Progression on Immune Checkpoint Inhibitor in Metastatic Urothelial Cancer
Treatment with the antibody-drug conjugate sacituzumab govitecan-hziy achieved an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer who experienced disease progression on an immune checkpoint inhibitor, according to the primary analysis of the...
Expert Point of View: Tyler Seibert, MD, PhD
Formal discussant of the FORMULA-509 trial, Tyler Seibert, MD, PhD, of the University of California San Diego, commented: “The important take-away of these results is who benefited from the intensification arm. The overall cohort with a PSA [prostate-specific antigen] level up to 0.5 ng/mL did not, ...
FORMULA-509: Intensified Postoperative Regimen May Be of Benefit in Subset of High-Risk Prostate Cancer
The addition of abiraterone acetate and apalutamide to standard of care gonadotropin-releasing hormone (GnRH) agonist for 6 months and radiation therapy failed to improve progression-free survival and metastasis-free survival after prostatectomy compared to bicalutamide plus a GnRH agonist and...
Colorectal Cancer Rates Are Rising in Younger Adults, Shifting to More Advanced Disease Across All Ages
According to the American Cancer Society, colorectal cancer is the third most commonly diagnosed cancer and the third most common cause of cancer-related death in both men and women in the United States. However, it ranks second in cancer-related deaths overall and is the leading cause of cancer...
Expert Point of View: Elena Castro, MD, PhD
The formal discussant of the TALAPRO-2 trial, Elena Castro, MD, PhD, took issue with the conclusion of Dr. Neeraj Agarwal and colleagues that these results support the use of talazoparib plus enzalutamide as a first-line treatment of patients with metastatic castration-resistant prostate cancer,...
TALAPRO-2: Talazoparib Plus Enzalutamide Extends Radiographic Progression–Free Survival in Metastatic Castration-Resistant Prostate Cancer
The addition of the poly (ADP ribose) polymerase (PARP) inhibitor talazoparib to the androgen receptor signaling inhibitor enzalutamide achieved a statistically significant and clinically meaningful improvement in radiographic progression–free survival compared with placebo plus enzalutamide as...
Michael Taylor, MD, PhD, Appointed Director at Texas Children’s Hospital and Baylor College of Medicine
Texas Children’s Hospital and Baylor College of Medicine recently named Michael Taylor, MD, PhD, molecular biologist and Cancer Prevention and Research Institute of Texas Scholar, as Director of the Pediatric Neuro-Oncology Research Program at Texas Children’s Hospital and Baylor College of...
